Kiora Pharmaceuticals Inc. - רווח נקי למניה אחת בשנים עשר החודשים האחרונים KPRX

Kiora Pharmaceuticals (KPRX) operates within a stable US legal framework, free from external political threats. Funding for the development of treatments for rare ocular pathologies relies on investment capital. Net income per share growth YoY over the last 12 months reflects a trend where -19.20 represents the latest level. The business creates a unique biopharmaceutical environment by utilizing patented KIO-301 light-sensitive molecules for the long-term treatment of patients.
KPRX (Kiora Pharma): פילוחים אנליטיים ודוחות לפי אינדיקטורים

The development dynamics of retinal drugs are directly reflected in the comparable year-over-year growth of EPS TTM for Kiora Pharmaceuticals (KPRX). This indicator measures the percentage change in earnings per share over the last twelve months, neutralizing short-term volatility. The metric reveals the impact of one-time fiscal factors on net income. This is critical for Kiora Pharmaceuticals (KPRX), as the current scaling of tests is increasing unit costs. The stability of this indicator confirms the fundamental resilience of the assets.